| Autor: |
Gandolfi S; Dana-Farber Cancer Institute, Boston, Massachusetts., Vekstein C; Dana-Farber Cancer Institute, Boston, Massachusetts., Laubach JP; Dana-Farber Cancer Institute, Boston, Massachusetts., O'Brien A; Dana-Farber Cancer Institute, Boston, Massachusetts., Masone K; Dana-Farber Cancer Institute, Boston, Massachusetts., Munshi NC; Dana-Farber Cancer Institute, Boston, Massachusetts., Anderson KC; Dana-Farber Cancer Institute, Boston, Massachusetts., Richardson PG; Dana-Farber Cancer Institute, Boston, Massachusetts. |
| Abstrakt: |
Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who are eligible for the procedure, and has contributed to improved overall survival. In the current era of novel therapies, the treatment landscape and prognosis have changed. The outstanding efficacy seen with regimens based on novel agents has led to a questioning of the frontline treatment paradigm with respect to ASCT. A key current question is whether to use transplant early or to collect stem cells early but save ASCT for salvage therapy. In this review, we evaluate the clinical data for each approach as well as the arguments in favor of early or delayed ASCT. We also consider the clinical/clonal heterogeneity of myeloma and review the evidence regarding which patient subgroups may benefit most from each approach. We summarize current treatment guidelines for transplant-eligible patients with NDMM and review the evolving role of minimal residual disease evaluation and its potential effect on the debate over early vs delayed ASCT. We conclude that frontline ASCT remains a standard of care for a substantial proportion of patients; however, delayed/salvage ASCT is increasingly being used in the context of highly active frontline regimens based on novel agents and the ongoing personalization of myeloma treatment. |
